BioNTech and DualityBio report modest PFS gain but higher lung toxicity in Phase 3 breast cancer trial
BioNTech SE and DualityBiologics announced that their Phase 3 DYNASTY‑Breast02 study met its primary goal, delivering a statistically significant yet limited improvement in progression‑free survival for patients with HR‑positive, HER2‑low metastatic breast cancer. The trial enrolled 541 participants and compared trastuzumab pamirtecan with standard chemotherapy. A higher incidence of interstitial lung disease, including a small number of severe and fatal cases, was observed, while overall survival data remain immature. The companies said they will review the results before deciding on further development steps.
Why it matters
The modest efficacy combined with safety concerns may temper expectations for the drug’s market potential, affecting investor sentiment toward BioNTech. No new efficacy or safety guidance was provided, so the immediate impact on the share price will depend on how the companies proceed.
Key facts
- 1The DYNASTY‑Breast02 trial randomized 541 patients to receive either trastuzumab pamirtecan or investigator‑chosen chemotherapy. stocktitan.net
- 2The study achieved its primary endpoint, showing a statistically significant but limited improvement in progression‑free survival. stocktitan.net
- 3Data for the secondary endpoint of overall survival were not mature at the time of the interim analysis. stocktitan.net
- 4A higher rate of interstitial lung disease was reported, with most events being Grade 1‑2 and a small proportion classified as severe or fatal. stocktitan.net
- 5BioNTech and DualityBio said they will discuss the findings and determine next steps. stocktitan.net
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.